Pablo Corral, Maria Gabriela Matta, Sebastian Garcia-Zamora, Natalia Nardelli, Nicolas F Renna, Juan Bautista Soumoulou, Santiago Lynch, Federico Salazar, Augusto Lavalle Cobo, Laura Schreier
Conventional apoB substantially underestimated weighted atherogenic burden in individuals with elevated Lp(a), with discordance increasing at higher concentrations. These findings support particle-specific weighting approaches for apoB-based cardiovascular risk assessment.
BACKGROUND AND AIMS: Apolipoprotein B (apoB) is the preferred marker of atherogenic particle burden, but it assumes that all apoB-containing lipoproteins confer the same cardiovascular risk. Mendelian randomization studies suggest that triglyceride-rich lipoproteins (TRLs) and lipoprotein(a) [Lp(a)] are more atherogenic per apoB particle than LDL. Risk-weighted apoB (RW-apoB) captures these differences in a single metric. We assessed the reclassification produced by RW-apoB versus measured apoB in the GAELp(a) registry, a real-world Lp(a)-enriched cohort.
METHODS: This post-hoc analysis of the GAELp(a) registry included 1861 adults with available apoB, Lp(a) expressed in nmol/L, and fasting triglycerides (TG) < 250 mg/dL. RW-apoB was calculated as: 11.65 × TG (mmol/L) + 0.215 × Lp(a) (nmol/L) + 0.736 × apoB (mg/dL). Reclassification was defined as the change in percentile rank between RW-apoB and measured apoB (Δ percentile). Analyses were stratified across five Lp(a) categories. A complementary analysis without TG truncation was performed in 1966 participants to evaluate the contribution of each RW-apoB component.
RESULTS: Mean apoB was 89.9 ± 27.6 mg/dL, whereas mean RW-apoB was 103.7 ± 36.3 mg/dL. Overall, 60.0% of participants were reclassified by ≥ 10 percentile points. In individuals with Lp(a) < 75 nmol/L, measured apoB slightly overestimated weighted atherogenic burden (median Δ percentile: -13.2). Conversely, apoB progressively underestimated weighted atherogenic burden with increasing Lp(a), reaching an RW-apoB/apoB ratio of 1.91 and median Δ percentile of +34.7 at Lp(a) ≥300 nmol/L. The reclassification pattern was virtually identical in the no-truncation analysis (60.0%), with Lp(a)-not TRL-identified as the primary driver of discordance between RW-apoB and measured apoB.
CONCLUSIONS: Conventional apoB substantially underestimated weighted atherogenic burden in individuals with elevated Lp(a), with discordance increasing at higher concentrations. These findings support particle-specific weighting approaches for apoB-based cardiovascular risk assessment.